viernes, 3 de marzo de 2017

Patient-derived xenografts: a relevant preclinical model for drug development | Journal of Experimental & Clinical Cancer Research | Full Text

Patient-derived xenografts: a relevant preclinical model for drug development | Journal of Experimental & Clinical Cancer Research | Full Text

Biomed Central

Journal of Experimental & Clinical Cancer Research

Patient-derived xenografts: a relevant preclinical model for drug development

Contributed equally
Journal of Experimental & Clinical Cancer Research201635:189
DOI: 10.1186/s13046-016-0462-4
Received: 29 October 2016
Accepted: 22 November 2016
Published: 5 December 2016

Abstract

Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the ‘right’ treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.

Keywords

Patient-derived-xenografts Immunosuppressed mice Subcutaneous Orthotopic Tumor heterogeneity Predictive value

No hay comentarios:

Publicar un comentario en la entrada